Truist Securities has lowered its rating on Nike, noting that recent financial results from sporting goods retailer DKS cast doubt on the athletic brand's broader business recovery strategy.
Several companies, including Oneok, Workday, Clearway Energy, MongoDB, Ferguson, and Kiniksa, have received updated price targets from various financial institutions.
Truist Securities has revised several stock ratings, raising targets for Jazz Pharmaceuticals and nCino based on clinical approvals and strong performance, while lowering its outlook for Intuit due to cautious guidance. The adjustments highlight shifting investor sentiment across healthcare, fintech, and software sectors.
Truist Securities suggests that shares of biotechnology company Biogen could see an increase if the company releases positive results from its recent trials for kidney and Alzheimer's treatments.
Truist Securities has adjusted its price target for Viridian Therapeutics (VRDN) from $40 to $36, indicating a revised outlook on the company's stock performance.
Truist Securities predicts that CoreWeave's shares will continue to rally and nearly double, even as Nvidia raises its GPU prices, due to sustained high demand for cloud-related infrastructure.
Truist Securities has identified TJX Companies and Ross Stores as top names within an attractive retail vertical, suggesting strong performance or investment potential in these discount retailers.
Truist Securities has updated its outlooks for Community Health Systems, Inc. (CYH) and The Pennant Group, Inc. (PNTG), noting stable demand trends for the latter within a broader sector update.
Truist Securities has issued a positive report on Arista Networks (ANET), emphasizing the company's strong position in AI networking and its promising growth outlook.
Truist Securities has initiated a buy rating for homebuilder Toll Brothers, projecting a 24% increase in its shares, driven by strength in the luxury housing market.